secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2024-01-25T23:59:59+00:00
Accession:  0001193125-24-015517
Event type: debt
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz reprices $2.72B term loans; margin cut 50 bps to Term SOFR+3.00%
---------------------------------------------------------------------

- Existing $2.7225B Initial Dollar Term Loans refinanced into same principal of Tranche B-1 Dollar Term Loans.
- New margin set at Term SOFR+3.00% (prime+2.00%), down from SOFR+3.50%; Term SOFR floor 0.50%.
- Additional $201.9M borrowed to repay Initial Dollar Term Loans that were not converted.
- Maturity unchanged at May 5, 2028; quarterly amortization at 0.2847% of initial principal.
- Repricing effective January 19, 2024; no change to covenants or security package.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312524015517/0001193125-24-015517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312524015517/d707707d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-015517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer